About this item:

103 Views | 45 Downloads

Author Notes:

Sherryl H. Goodman, Department of Psychology, 36 Eagle Row, Emory University, Atlanta, GA 30322. Email: psysg@emory.edu

This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE-1937971 and by the National Institute of Mental Health (K01 MH112876) and National Institute of Mental Health (1 P50 MH077928-01A1).

Authors Cochran, Pingeton, Goodman, and Laurent have no conflicts of interest to disclose. Dr. Rathouz has a regular appointment on a Data Safety Board for Sunovion Pharmaceuticals. Dr. Newport has received research support from Eli Lilly, Glaxo SmithKline (GSK), Janssen, the National Alliance for Research on Schizophrenia and Depression (NARSAD), the National Institutes of Health (NIH), SAGE, Takeda Pharmaceuticals, the Texas Health & Human Services Commission, and Wyeth. He has served on speakers’ bureaus and/or received honoraria from Astra-Zeneca, Eli Lilly, GSK, Pfizer and Wyeth. He has served on advisory boards for GSK, Janssen, and Sage Therapeutics. He has never served as a consultant to any biomedical or pharmaceutical corporations. Neither he nor family members have ever held equity positions in biomedical or pharmaceutical corporations. Dr. Stowe has received research support from NIH, CDC, GSK, Pfizer, Wyeth, Janssen and SAGE; has served on speaker or advisory boards for Pfizer, Eli Lilly, Wyeth, SAGE, BMS, and GSK; and has received honoraria from Eli Lilly, GSK, Pfizer, and Wyeth.

Subject:

Keywords:

  • Adult
  • Anxiety
  • Concept Formation
  • Depression
  • Depression, Postpartum
  • Factor Analysis, Statistical
  • Female
  • Humans
  • Mood Disorders
  • Postpartum Period
  • Pregnancy
  • Pregnancy Complications
  • Prospective Studies
  • Sleep Wake Disorders

A transdiagnostic approach to conceptualizing depression across the perinatal period in a high-risk sample

Tools:

Journal Title:

Journal of Abnormal Psychology

Volume:

Volume 129, Number 7

Publisher:

, Pages 689-700

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Clinical guidelines recommend assessing depression during pregnancy and postpartum but often overlook potential changes in symptoms across this developmental period. Such changes contribute to difficulties in conceptualizing maternal depression. This study aimed to situate depressive symptoms and related concerns (anxiety, stress, sleep) across the perinatal period within a transdiagnostic framework and to use this framework to better understand how depressive symptoms change across the perinatal period. First, items from seven symptom scales were a priori categorized into six transdiagnostic factors: four based on Research Domain Criteria (loss, potential threat, frustrative nonreward, and sleep-wakefulness) and two based on the depression literature (somatic and coping symptoms). Second, using prospective data from women with a history of an affective disorder (n = 657) in an observational study of neuropsychiatric illness, factor analyses were performed in seven periods (three trimesters of pregnancy and four quarters of first year postpartum). For each period, a bifactor model with six transdiagnostic factors and a general factor fit data better than models that combined or dropped a factor (p <.003). Except around delivery, item loadings and intercepts could be fixed between consecutive periods and still adequately fit data from both periods. Means of sleep-wakefulness and somatic factors increased significantly from second to third trimester (p<.01), with trends reversing early postpartum. In conclusion, depressive symptoms and related concerns exhibit factor structures that are only partly congruent across the perinatal period. This conclusion suggests that greater attention to specific life phases is warranted in the conceptualization of depression during this time in women's lives.
Export to EndNote